Intra-Cellular Therapies News

Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS)

GlobeNewswireApr 30 08:00 ET

Press Release: Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- I

Dow JonesApr 24 16:01 ET

Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Overweight and maintains $120 price target.

BenzingaApr 24 09:57 ET

Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Intra-Cellular Therapies (ITCI)

TipRanksApr 24 08:50 ET

Intra-Cellular Therapies Is Maintained at Buy by Canaccord Genuity

Intra-Cellular Therapies Is Maintained at Buy by Canaccord Genuity

Dow JonesApr 23 10:58 ET

Express News | Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $107

Moomoo 24/7Apr 23 10:49 ET

Express News | Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90

Moomoo 24/7Apr 22 12:44 ET

10 Best Performing Biotech ETFs in 2024

Yahoo FinanceApr 22 11:10 ET

Buy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder Market

TipRanksApr 22 10:05 ET

The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI) in the last three months.The table below offers a conden

BenzingaApr 22 09:00 ET

Express News | Intra-Cellular Therapies Inc : Mizuho Raises Target Price to $96 From $82

Moomoo 24/7Apr 22 06:41 ET

How Is The Market Feeling About Intra-Cellular Therapies?

Intra-Cellular Therapies's (NYSE:ITCI) short percent of float has risen 4.8% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 4.15% of all regu

BenzingaApr 19 12:00 ET

Analysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)

TipRanksApr 18 21:50 ET

Top Gap Ups and Downs on Thursday: TSM, ELV, MMC and More

Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.

moomoo NewsApr 18 19:28 ET

Express News | Intra-Cellular Therapies Shares Are Trading Lower After the Company Priced a $500 Million Offering

Moomoo 24/7Apr 18 15:42 ET

Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)

TipRanksApr 18 08:20 ET

Express News | Reported Earlier, Intra-Cellular Therapies Prices Public Offering Of 6,849,316 Common Shares At $73/Share

Moomoo 24/7Apr 18 03:42 ET

Intra-Cellular Therapies Drops 2%, Prices $500M Equity Financing

Seeking AlphaApr 18 02:47 ET

Express News | Intra-Cellular Therapies Inc : Jefferies Raises Target Price to $105 From $100

Moomoo 24/7Apr 18 02:22 ET

All Shares in Offering Will Be Sold by Intra-Cellular Therapies >ITCI

All Shares in Offering Will Be Sold by Intra-Cellular Therapies >ITCI

Dow JonesApr 17 21:16 ET